News Updates
More Articles
- CHMP recommends deucravacitinib for plaque psoriasis
- CHMP backs Sandoz's high-concentration adalimumab
- Efanesoctocog alfa shows effectiveness in hemophilia
- Forged labels linked to contaminated cough syrup
- Pfizer backs Ribon Therapeutics with $25M investment
UK grants GMP certification to cannabis API facility
The UK Medicines and Healthcare products Regulatory Agency certified Celadon's good manufacturing practice facility in the country's Midlands region to manufacture a cannabis-derived active pharmaceutical ingredient. "With the receipt of GMP registration, Celadon has joined a very select group of cannabis-focused pharmaceutical companies globally," said company CEO James Short. PharmaTimes magazine (UK) (1/16)
Read full article now.
×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!